Skip to main content

Affibody AB and AbClon enter into a License Agreement regarding the Affibody® Technology

Pressmeddelande   •   Jun 05, 2013 09:00 CEST

Seoul, South Korea and Solna, Sweden, June 5, 2013.

Affibody AB and AbClon Inc. have signed a License Agreement regarding the use of Affibody’s proprietary technology platforms: Affibody® molecules and AlbumodTM for use in combination with AbClon’s proprietary and/or generic anti-cancer antibodies.

Our relationship with AbClon will provide the foundation for a very interesting use of our technology”, commented David Bejker, CEO of Affibody. “We are excited to work with AbClon to develop a new class of therapeutic molecules, AffiMabs, that can be a game changer in oncology.”

AffiMabs are innovative molecules generated from engineering of Affibody® molecules / AlbumodTM into therapeutic antibodies. Affibody and AbClon will focus on development of AffiMabs as next generation therapeutic antibodies for cancer.

More than we can imagine, AffiMab will become a vital breakthrough in the fight against cancer as creative therapeutic toolbox. Affibody’s technology platform is an outstanding and inevitable choice with AbClon’s antibodies for AffiMab”, mentioned Jong-Seo Lee, CEO of AbClon.

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Sobi, GE, Daewoong and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor AB.

Further information can be found at: www.affibody.com

Bifogade filer

PDF-dokument

Kommentarer (0)

Lägg till kommentar

Kommentera